EVALUATION OF THE PAIN MANAGEMENT EFFICIENCY AFTER PRIMARY HIP ARTHROPLASTY: RESULTS OF KVEST PROJECT

Abstract

Introduction. Celecoxibum being one of high-selective COX-2 inhibitors is specifically inhibiting COX-2 in vivo not influencing protective effect of COX-1. Celecoxibum systemic administration after primary arthroplasty in combination with local infiltration anesthesia has a number of advantages. Purpose of the study. To evaluate the efficiency of postoperative pain relief by Celecoxibum in primary hip arthroplasty using standard and minimally invasive approaches as well as to analyze the pain syndrome dynamics by a method of local infiltration anesthesia (LIA).Material and methods. The study included 91 patients with hip arthritis of grade III-IV without severe anatomical alterations who underwent primary hip arthroplasty in the Vreden Research institute of traumatology and orthopaedics during 2017. Patients were randomized by type of surgical approach used (standard or minimally invasive), the authors compared monotherapy by Celecoxibum with a multimodal anesthesia which included systemic Celecoxibum administration in combination with LIA. Additional evaluation of two LIA methods was conducted in the group of patients with standard approach.Results. Pain syndrome dynamics was comparable in all groups — minimal intensity within first day after the surgery and almost complete absence of pain on day 7. However, on day 3 variance between the subgroups increased: the best outcome was observed in the group of minimally invasive approach combined with LIA VAS score was 1.0 (95% CI, 0–1); in the group with standard approach without LIA VAS score was 4.5 (95% CI, 2–7); in the group with standard approach with a single LIA VAS score was 2.6 (95%CI, 0–5); in the group with standard approach with threestage LIA VAS score was 2.4 (95%CI, 0–5); in the group with minimally invasive approach without LIA VAS score was 3,9 (95% CI, 0–2). On day 7 the parameters in all groups demonstrated no statistically significant variances with a minor elevation in cases when LIA was not performed and with average VAS score of 0.8 (95% CI, 0–4). By day 14 pain syndrome was absent or within a range of 1 point in all patients, by this treatment stage Celecoxibum medication was stopped in 37 out of 91 patients (40.7%).Conclusion. Administration of Celecoxibum per os (200 mg twice per 24 hours) in combination with LIA by Ropivacaine and dexamethasone solution in primary hip arthroplasty provides fast relief of pain facilitating early mobilization of patients and accelerated rehabilitation. Celecoxibum safety in therapeutic dose was also proven.